Ignite Creation Date:
2024-05-06 @ 3:26 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04630769
Status:
COMPLETED
Last Update Posted:
2023-04-03
First Post:
2020-11-11
Brief Title:
FT516 and IL2 With Enoblituzumab for Ovarian Cancer
Sponsor:
Masonic Cancer Center University of Minnesota
Organization:
Masonic Cancer Center University of Minnesota
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Primary Peritoneal Cavity Cancer |
| Ovarian Cancer |
| Fallopian Tube Adenocarcinoma |
Keywords: